---
document_datetime: 2026-01-28 12:45:56
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dexdor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dexdor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2388845
conversion_datetime: 2026-01-29 12:20:02.804664
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dexdor

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 26/01/2026                          |                                             | Labelling and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000320486                      | Update of the package leaflet with revised contact details of local representatives and to delete 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4. Additionally, the MAH took the opportunity to make minor editorial amendments and implement changes to the prefixes for batch number and expiry date in the labelling under 'Particulars to appear on the outer packaging (carton)' and 'Minimum particulars to appear on small immediate packaging units (ampoules or vials)' in line with QRD Appendix IV.   |            |     | PL   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000292342 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minor change to the restricted part of an                                      | 04/12/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                       | Active Substance Master File - Accepted B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                               |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000268932 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to update RMP to add category 3 study as additional PhV measure as requested in the outcome of PAM-LEG 016.7 - EMEA/H/C/002268/LEG/016.7 AR. Additionally, in line with EMEA/H/C/PSUSA/00000998/202403 outcome, MAH took the opportunity to update the EU RMP to remove the following issues from the summary of safety concerns : • Cortisol suppression • | 05/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Convulsions • Hypothermia Minor editorial changes have been done to the RMP as well.   |
|----------------------------------------------------------------------------------------|